In June 2010, MCS conducted media relations activities for client MannKind Corporation at the American Diabetes Association’s 70th Scientific Sessions, where Phase III data were being presented for MannKind’s lead investigational product, AFREZZA™ – a novel, ultra rapid acting insulin being developed for adult patients with diabetes that is currently under regulatory review by the FDA.

MCS’ mission was to seize the spotlight from other significant ADA news, including major, controversial clinical trials, to help build awareness of AFREZZA within the diabetes community. To ensure that AFREZZA was one of the meeting’s top newsmakers, MCS leveraged the 12 AFREZZA abstracts that were being presented at ADA, one of which included an abstract highlighted in The Lancet, the world’s leading medical journal, and presented during a special ADA symposium. Highlighting AFREZZA’s unique attributes and the latest clinical findings, MCS developed press materials and conducted remote and onsite media relations to secure 10 interviews for MannKind executives and positive coverage in dozens of top mainstream, trade and social media outlets, including FOX News, Medscape Medical News, XM Radio and the blog Diabetes Mine, reaching an audience of over 400 million to date.

This entry was posted on Monday, August 23rd, 2010 at 3:38 pm and is filed under Client News, other. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.